At the news
? NEUTRALIMPACT 3/10 8-K filed Sep 14, 2026 at 07:15 ET
Q32 Bio announced the appointment of Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer, both with strong late-stage development and regulatory backgrounds. The hires signal the company's transition toward a registration-directed program for bempikibart in alopecia areata, with a registrational trial expected in the first half of 2027. This is a routine executive appointment with no financial data or material business changes disclosed, making it a neutral event for traders.
- Q32 Bio appointed Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer on September 14, 2026.
- Dr. Trevejo previously served as CMO at Tarsus Pharmaceuticals, where he helped lead the FDA approval and launch of XDEMVY.
- Dr. Hershberger previously served as CDO at Adagio Therapeutics (now Invivyd), contributing to its IPO that raised approximately $356 million in gross proceeds.
- The company plans to advance bempikibart into a registration-directed program for severe or very severe alopecia areata in the first half of 2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access